Nirsevimab for preventing respiratory syncytial virus infection in a periviable extremely preterm infant
10.3760/cma.j.cn113903-20250831-00482
- VernacularTitle:尼塞韦单抗预防生存极限超早产儿呼吸道合胞病毒感染1例
- Author:
Yanqing LIN
1
;
Xuran WANG
1
;
Zhifeng HUANG
1
;
Haifeng ZONG
1
;
Xiaoyun XIONG
1
;
Chuanzhong YANG
1
Author Information
1. 南方医科大学妇女儿童医学中心（深圳市妇幼保健院）新生儿重症监护病房，深圳 518028
- Publication Type:Journal Article
- Keywords:
Periviable;
Extremely preterm birth;
Respiratory syncytial virus;
Nirsevimab
- From:
Chinese Journal of Perinatal Medicine
2025;28(12):1062-1064
- CountryChina
- Language:Chinese
-
Abstract:
This report described a periviable extremely preterm infant who received Nirsevimab before discharge for preventing respiratory syncytial virus infection. The infant was born at 22?3 weeks' gestation with a birth weight of 360 g. Nirsevimab was administered on January 12, 2025 (110 days after birth, corrected gestational age of 38?2 weeks) at the Women and Children's Medical Center of Southern Medical University (Shenzhen Maternity & Child Healthcare Hospital). No local or systemic adverse reactions were observed following administration. Follow-up until 1 year and 2 months of age (November 2025) revealed no occurrence of respiratory syncytial virus infection.
